#	Pagina
attuale pagina	/open-h2020/projects/196375/index.html

Opendata, web and dolomites

EbolaVac SIGNED

Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

EbolaVac project word cloud

Explore the words cloud of the EbolaVac project. It provides you a very rough idea of what is the project "EbolaVac" about.

3431 zaire nigeria heavily children chad3 west outbreaks wp4 stage world reside health countries sierra september percent outbreak frontline 22 data evaluation risk capacity organization ebolavac prevention 7470 ebo senegal effect license ebolavirus virus 2014 line chimpanzee adults innovative safe pressure clinical accelerate outside appropriate quality adenovirus disease immunological ebola wp5 centrally assist total reports candidate besides declared vaccination logistical complete switzerland guinea march liberia front requested attempting leone time engage fatalities care interventions coordinated standards august efforts vaccine maintaining estimates containment supporting evd epidemic deaths first occurred true workers centers lausanne doubling reported booster innovation days ebov ten gsk times wp3 contain africa wp2

Project "EbolaVac" data sheet

The following table provides information about the project.

Coordinator	GLAXOSMITHKLINE BIOLOGICALS SA Organization address address: RUE DE L INSTITUT 89 city: RIXENSART postcode: 1330 website: www.gskbio.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Project website	http://www.ebolavac.eu
Total cost	22˙055˙090 €
EC max contribution	15˙153˙216 € (69%)
Programme	1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
Code Call	H2020-Adhoc-2014-20
Funding Scheme	RIA
Starting year	2014
Duration (year-month-day)	from 2014-10-07 to 2018-04-06

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	GLAXOSMITHKLINE BIOLOGICALS SA GLAXOSMITHKLINE BIOLOGICALS SA Organization address address: RUE DE L INSTITUT 89 city: RIXENSART postcode: 1330 website: www.gskbio.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (RIXENSART)	coordinator	14˙103˙135.00
2	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Organization address address: WELLINGTON SQUARE UNIVERSITY OFFICES city: OXFORD postcode: OX1 2JD website: www.ox.ac.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (OXFORD)	participant	942˙581.00
3	BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN Organization address address: BERNHARD NOCHT STRASSE 74 city: HAMBURG postcode: 20359 website: www.bni.uni-hamburg.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	107˙500.00
4	CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS Organization address address: RUE DU BUGNON 21 city: LAUSANNE postcode: 1005 website: www.chuv.ch contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (LAUSANNE)	participant	0.00

Map

Project objective

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and estimates the true number of cases at 2.5 times higher than that reported. Countries that have been affected are Guinea, Liberia, Nigeria, Senegal and Sierra Leone. Ten percent of fatalities have occurred among front line health care workers attempting to contain the epidemic. On 7 August 2014, the WHO requested that GSK “fully engage in WHO-coordinated efforts to test, license and make available safe and effective Ebola interventions” to assist in the control of the outbreak. Taking into account the early stage of development, EbolaVac seeks to accelerate the clinical development of the GSK chimpanzee adenovirus type 3 Ebolavirus Zaire (ChAd3-EBO Z) vaccine candidate to make the vaccine available to frontline health care workers at risk and to be used in the containment of EBOV outbreaks. The project specifically aims to: (i) complete Phase 1 development of the ChAd3-EBO Z vaccine by supporting a clinical study conducted in Lausanne, Switzerland (WP2); (ii) evaluate the ChAd3-EBO Z vaccine in Phase 2 testing on adults and children at established clinical study centers in West Africa outside the current most heavily affected countries of Guinea, Sierra Leone, and Liberia (WP3); (iii) investigate immunological effects of vaccination and the effect of booster vaccination (WP4) and (iv) centrally manage and analyse clinical study data (WP5). Besides using an innovative vaccine technology, much of the innovation of this program will reside in its capacity to implement vaccine evaluation under significant time pressure and complex logistical challenges while maintaining appropriate quality standards.

Deliverables

List of deliverables.
Web based platform live	Websites, patent fillings, videos etc.	2019-04-18 14:34:37
Report on status of posting results in the study registry	Documents, reports	2019-04-18 14:34:27
Registration No. of Senegal clinical study in a WHO or ICMJE approved registry	Documents, reports	2019-04-18 14:34:30
Registration number of clinical trial in ClinicalTrials.gov and Swiss National Clinical Trials Portal	Documents, reports	2019-05-30 11:34:49
Clearances from ethic committees and regulatory authorities	Documents, reports	2019-05-30 11:34:48
Clinical study report	Documents, reports	2019-04-15 16:23:44

Take a look to the deliverables list in detail: detailed list of EbolaVac deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2017	Teresa Lambe, Georgina Bowyer, Katie J Ewer A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? published pages: 20160295, ISSN: 0962-8436, DOI: 10.1098/rstb.2016.0295	Philosophical Transactions of the Royal Society B: Biological Sciences 372/1721	2019-07-02

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBOLAVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBOLAVAC" are provided by the European Opendata Portal: CORDIS opendata.